People · Operator

Susan Holleran

Named in public records as an officer, director or promoter · active 2025–2025 · Other Technology

1
Companies
1
Filings
$60.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
RedShift BioAnalytics, Inc.Other TechnologySeries B$60.5M$31.7M2025
Operator network

Susan Holleran at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Bryson Hollimon · 4 companies · 1 sharedBryson HollimonFrank Smith · 4 companies · 1 sharedFrank SmithWilliam Cadogan · 3 companies · 1 sharedWilliam CadoganAmol Chaubal · 2 companies · 1 sharedAmol ChaubalCharles Purtell · 2 companies · 1 sharedCharles PurtellDon Bossi · 2 companies · 1 sharedDon BossiPaul Tardif · 2 companies · 1 sharedPaul TardifBryson Holliman · 1 companies · 1 sharedBryson HollimanCharles Marshall · 1 companies · 1 sharedCharles MarshallEugene Ma · 1 companies · 1 sharedEugene MaJulien Bradley · 1 companies · 1 sharedJulien BradleyMark Cafazzo · 1 companies · 1 sharedMark CafazzoRob Carson · 1 companies · 1 sharedRob CarsonThomas O'Lenic · 1 companies · 1 sharedThomas O'LenicWouter Meuleman · 1 companies · 1 sharedWouter MeulemanRedShift BioAnalytics, Inc. · $60.5M raisedRedShift BioAnalytics…Susan HolleranSH
Susan Holleran Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Susan Holleran on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Bryson Hollimon14
Frank Smith14
William Cadogan13
Amol Chaubal12
Don Bossi12
Charles Purtell12
Paul Tardif12
Wouter Meuleman11
Thomas O'Lenic11
Mark Cafazzo11
Bryson Holliman11
Julien Bradley11
Eugene Ma11
Rob Carson11
Charles Marshall11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.